<DOC>
	<DOCNO>NCT00790400</DOCNO>
	<brief_summary>This study evaluate safety efficacy RAD001 treat patient Angiomyolipoma associate Tuberous Sclerosis Complex Sporadic Lymphangioleiomyomatosis .</brief_summary>
	<brief_title>Efficacy Safety RAD001 Patients Aged 18 Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex ( TSC ) Sporadic Lymphangioleiomyomatosis ( LAM )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Lymphangioleiomyomatosis</mesh_term>
	<mesh_term>Angiomyolipoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male Female 18 year old Clinically definite diagnosis Tuberous Sclerosis Complex accord modify Gomez criterion sporadic LAM ( biopsyproven compatible chest CT scan ) Clinically definite diagnosis renal angiomyolipoma At least one Angiomyolipoma â‰¥ 3 cm long diameter use CT MRI Females child bear potential must use birth control documentation negative pregnancy test Written inform consent accord local guideline Recent heart attack , cardiac relate chest pain stroke Severely impaired lung function Bleeding related angiomyolipoma embolization 6 month prior randomization Clinically significant chylous ascites Clinically significant hematological hepatic abnormality Severe liver dysfunction Severe kidney dysfunction Pregnancy breast feed Current infection History organ transplant Surgery within two month prior study enrollment Prior therapy medication class Everolimus Recent use investigational drug Bleeding diathesis oral antivitamin K medication Uncontrolled high cholesterol Uncontrolled diabetes HIV Inability attend schedule clinic visit Patients metal implant thus prohibit MRI evaluation Angiomyolipoma require surgery time randomization History malignancy Severe uncontrolled medical condition would cause unacceptable safety risk compromise compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Angiomyolipoma</keyword>
	<keyword>AML</keyword>
	<keyword>Tuberous Sclerosis Complex</keyword>
	<keyword>TSC</keyword>
	<keyword>mTOR</keyword>
	<keyword>RAD001</keyword>
	<keyword>Mammalian Target Rapamycin</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Afinitor</keyword>
	<keyword>SEGA</keyword>
	<keyword>Subependymal Giant Cell Astrocytoma</keyword>
	<keyword>Seizures</keyword>
	<keyword>Tuberous sclerosis complex ( TSC )</keyword>
	<keyword>Tuberous sclerosis</keyword>
	<keyword>benign tumor brain</keyword>
	<keyword>kidney</keyword>
	<keyword>heart</keyword>
	<keyword>eye</keyword>
	<keyword>lung</keyword>
	<keyword>skinTSC1</keyword>
	<keyword>TSC2</keyword>
	<keyword>hamaratin</keyword>
	<keyword>tuberin , tumor growth suppressor</keyword>
	<keyword>gyrus</keyword>
	<keyword>tuber</keyword>
	<keyword>Sporadic Lymphangioleiomyomatosis .</keyword>
	<keyword>Lymphangioleiomyomatosis ( LAM )</keyword>
	<keyword>rare lung disease</keyword>
</DOC>